Galderma Showcases Cutting-edge Advancements in Aesthetics Portfolio at IMCAS 2024, Strengthening Leadership Position

Galderma is set to unveil the latest advancements from its expansive portfolio at the IMCAS World Congress 2024, scheduled from February 1-3, 2024, in Paris. These updates solidify Galderma’s leadership in aesthetic injectables and dermatological skincare. The presentation encompasses 10 research posters, featuring data from the entire portfolio, including the investigational neuromodulator RelabotulinumtoxinA.

The focus of the presentation will extend beyond showcasing research, with Galderma hosting a series of events tailored to address the genuine needs of physicians. This includes three symposia, ‘Meet the Expert’ sessions, and interactive booth engagements. The spotlight will be on RelabotulinumtoxinA, a neuromodulator developed over 15 years to enhance Galderma’s leadership in neuromodulation and create an optimal neuromodulator for aesthetic purposes.

Results from the phase III READY-1 and READY-2 studies will be presented, demonstrating the high efficacy and tolerability of RelabotulinumtoxinA in treating moderate to severe glabellar lines and lateral canthal lines. Rapid onset, sustained results through six months, and high patient satisfaction were notable, with low rates of treatment-related adverse events compared to placebo.

The READY clinical trial program comprises four phase III trials with over 1,900 participants, and the data will be presented as an e-poster throughout the conference at the Open Stage Library.

In addition to research presentations, Galderma will conduct three symposia to showcase innovations, scientific insights, and educational initiatives supporting the aesthetics community. These symposia include “Our Aesthetic Lives – Pushing the Boundaries in Aesthetics,” “Skin Science by Galderma Medical Affairs,” and “AART™ of Sculptra.”

The company will also celebrate the 25th anniversary of Sculptra, the original injectable biostimulator with PLLA-SCA™ microparticles. Numerous posters on Sculptra, covering its mode of action and efficacy in non-facial areas, will be presented at IMCAS. Galderma remains committed to advancing holistic individualized treatments and will host ‘Meet the Expert’ sessions exploring various treatment protocols from its portfolio, such as Kiss & Smile™, SHAPE UP™, and CTMP™, along with products like ALASTIN Skincare®, Restylane®, and Sculptra. The presentations underscore Galderma’s dedication to innovation and scientific excellence in the field of aesthetics.

Source Link